NASDAQ:VIVO - Meridian Bioscience Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $30.50
  • Forecasted Upside: 63.98 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$18.60
▲ +0.15 (0.81%)

This chart shows the closing price for VIVO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Meridian Bioscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VIVO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VIVO

Analyst Price Target is $30.50
▲ +63.98% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Meridian Bioscience in the last 3 months. The average price target is $30.50, with a high forecast of $34.00 and a low forecast of $27.00. The average price target represents a 63.98% upside from the last price of $18.60.

This chart shows the closing price for VIVO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Meridian Bioscience. This rating has held steady since October 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/8/2021HC WainwrightReiterated RatingBuy$27.00Low
8/9/2021HC WainwrightLower Price TargetBuy$30.00 ➝ $27.00Medium
7/26/2021HC WainwrightReiterated RatingBuy$30.00Medium
6/29/2021HC WainwrightReiterated RatingBuy$30.00High
5/10/2021HC WainwrightLower Price TargetBuy$32.00 ➝ $30.00High
2/24/2021HC WainwrightLower Price TargetBuy$34.00 ➝ $32.00High
2/8/2021HC WainwrightReiterated RatingBuy$30.00 ➝ $34.00Medium
2/8/2021Piper SandlerBoost Price TargetOverweight$26.00 ➝ $34.00Medium
1/19/2021HC WainwrightReiterated RatingBuy$30.00Low
11/16/2020Piper SandlerBoost Price TargetOverweight$24.00 ➝ $26.00Medium
11/16/2020HC WainwrightLower Price TargetBuy$34.00 ➝ $30.00High
9/18/2020HC WainwrightReiterated RatingBuy$34.00High
7/27/2020HC WainwrightInitiated CoverageBuy$34.00High
5/11/2020William BlairUpgradeMarket Perform ➝ OutperformLow
2/8/2020William BlairReiterated RatingMarket PerformMedium
11/19/2019Canaccord GenuityReiterated RatingSell$8.00Low
7/31/2019Canaccord GenuityReiterated RatingSell$9.00Low
6/5/2019Canaccord GenuityReiterated RatingBuy$1.80Low
5/1/2019Canaccord GenuityLower Price TargetSell ➝ Sell$11.00 ➝ $9.00Medium
5/1/2019Piper Jaffray CompaniesUpgradeUnderweight ➝ Neutral$15.00 ➝ $11.00High
4/3/2019Robert W. BairdLower Price TargetNeutral$17.00 ➝ $14.00High
4/3/2019Canaccord GenuityDowngradeHold ➝ Sell$17.00 ➝ $11.00High
4/2/2019Piper Jaffray CompaniesLower Price TargetUnderweight$17.00 ➝ $15.00High
1/26/2018Canaccord GenuityBoost Price TargetHold ➝ Hold$14.00 ➝ $16.00Low
10/13/2017Canaccord GenuityReiterated RatingHold$14.00N/A
5/3/2017Canaccord GenuityBoost Price TargetHold$13.00 ➝ $15.00Low
3/28/2017CL KingInitiated CoverageNeutral ➝ NeutralHigh
1/31/2017Craig HallumDowngradeBuy ➝ HoldN/A
1/25/2017Piper Jaffray CompaniesSet Price TargetSell$9.00N/A
11/14/2016Craig HallumDowngradeBuy ➝ Hold$19.00N/A
(Data available from 10/24/2016 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/27/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2021
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/25/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/24/2021
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2021

Current Sentiment

  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Meridian Bioscience logo
Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products; and sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.
Read More

Today's Range

Now: $18.60
Low: $18.20
High: $18.68

50 Day Range

MA: $19.49
Low: $17.86
High: $20.69

52 Week Range

Now: $18.60
Low: $15.45
High: $30.65

Volume

150,760 shs

Average Volume

565,496 shs

Market Capitalization

$806.38 million

P/E Ratio

11.48

Dividend Yield

N/A

Beta

0.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Meridian Bioscience?

The following sell-side analysts have issued reports on Meridian Bioscience in the last year: HC Wainwright, Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for VIVO.

What is the current price target for Meridian Bioscience?

2 Wall Street analysts have set twelve-month price targets for Meridian Bioscience in the last year. Their average twelve-month price target is $30.50, suggesting a possible upside of 64.0%. Piper Sandler has the highest price target set, predicting VIVO will reach $34.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $27.00 for Meridian Bioscience in the next year.
View the latest price targets for VIVO.

What is the current consensus analyst rating for Meridian Bioscience?

Meridian Bioscience currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VIVO will outperform the market and that investors should add to their positions of Meridian Bioscience.
View the latest ratings for VIVO.

What other companies compete with Meridian Bioscience?

How do I contact Meridian Bioscience's investor relations team?

Meridian Bioscience's physical mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company's listed phone number is (513) 271-3700 and its investor relations email address is [email protected] The official website for Meridian Bioscience is www.meridianbioscience.com.